Available to designate orphan drugs only with approval of clinical trial plan
On the 18th, the Ministry of Food and Drug Safety(MFDS) pre-announced a revision bill to the ‘Regulations for Orphan Drug Designation’ which contains articles of improving regulations which allows health care authorities to designate a drug as orphan drug only with approval of clinical trial plan...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
